One Partner, Every Step Of Your ADC Program

Most ADC programs stitch together separate vendors for antibody, payload chemistry and conjugation. We run all three in-house, with one team and one quality system, from early discovery through cGMP clinical supply.

We handle high-potency and cytotoxic compounds up to OEB-5, enabling fully integrated ADC development and manufacturing under a single team and quality system from early discovery through cGMP clinical supply.

Capabilities

Built around your molecule, at every stage

Bioconjugation Discovery

• Antibody discovery: hybridoma, single B-cell, display platforms
• ADC chemistry: linker & payload design and synthesis
• Bioconjugation: lysine, cysteine, site-specific, enzymatic
• Assay biology: in vitro cell killing, immune modulation
• DMPK and in vivo: LC-MS, bioassay, in vivo efficacy

Payload & Linker Chemistry

• Cytotoxic: tubulin-binders, DNA alkylators, topoisomerase inhibitors
• Non-cytotoxic: immune stimulants, kinase inhibitors, PROTACs
• Cleavable, non-cleavable, and enzyme-cleavable linker chemistries
• Linker selection for solubility, stability, and ADC aggregation

Bioconjugation Development

• Amine (lysine) and thiol (cysteine) conjugation
• Site-specific (THIOMAB) and enzymatic (transglutaminase, Sortase A) conjugation
• Click chemistry, Diels-Alder and dual-drug conjugation
• Click chemistry, Diels-Alder and dual-drug conjugation

GMP Manufacturing & Facilities

• Single-use Bioconjugation/ADC suite, closed processes

• Advanced containment designed for high-potency compounds
• Streamlined technology transfer through to GMP batch delivery
• End-to-end mAb capability; cell line development through GMP DS

Analytical & QC

• Release: purity, DAR, charge profile, impurities, endotoxin, bioburden

• Characterization: secondary/tertiary structure, peptide mapping, DLS
• DAR assay methods benchmarked against marketed and clinical-stage ADCs
• Platform: Bruker Maxis III, Agilent QToF, Waters Synapt G2-Si

Expert Support

Our scientists actively support multiple global programs across proprietary and non-proprietary chemistries beyond those listed here.

Beyond conventional ADCs

Next-generation conjugates beyond traditional ADCs

Degrader Antibody Conjugate (DAC)

A targeted modality that links an antibody to a small-molecule degrader, combining the precision of ADCs with catalytic, intracellular degradation.

• End-to-end DAC / ABTAC platform and workflow
• Customizable cleavable linker designs
• Site-specific conjugation, including THIOMAB
• In vitro screening across multiple DAC constructs

Dual-Payload ADCs

Distinct payloads delivered on one antibody, designed to overcome tumor heterogeneity and reduce acquired resistance while preserving targeted safety.

• Payload ratio and combination design
• Linker stability across both payloads
• Drug-to-antibody ratio optimization
• Synergistic efficacy with targeted delivery

Antibody-oligo Conjugates (AOCs)

AOCs combine the targeting precision of antibodies with the therapeutic potential of oligonucleotides, enabling selective delivery of RNA-based payload to specific tissue and cell types.

• Conjugation process development (cysteine, lysine or enzymatic)
• Payload ratio and combination design
• Drug-to-antibody ratio optimization (controlling DAR and DAR distribution across batches)
• Developing robust analytical methods for characterization of conjugation sites, occupancy, DAR, purity and potency

Protein-Drug Conjugates (PDCs)

PDCs expands the possibilities of targeted therapeutics beyond monoclonal antibodies by leveraging diverse protein scaffolds to deliver potent payloads with enhanced tissue penetration and tailored pharmacokinetics. combine the targeting precision of antibodies with the therapeutic potential of oligonucleotides, enabling selective delivery of RNA-based payload to specific tissue and cell types.

• Conjugation process development and optimization
• Linker and Payload selection
• Drug-to-protein ratio optimization
• Developing robust analytical methods for characterization of conjugation sites, occupancy, DAR, purity and potency

Dual-Payload APCs

APCs represent an emerging class of targeted therapeutics that combine the specificity of monoclonal antibodies with unique biological functions of protein payload, such as cytokines, enzyme, growth factors or other therapeutics proteins. APCs have the potential to enhance efficacy while minimizing systemic toxicity across oncology, immunology and other therapeutic areas.

• Payload ratio and combination design
• Linker stability across both payloads
• Drug-to-antibody ratio optimization
• Synergistic efficacy with targeted delivery

Why Syngene

Next-generation conjugates beyond traditional ADCs

Single-Source

Antibody, peptide, oligonucleotide, payload, linker and conjugation managed under one roof, minimizing risk and delays.

Diverse Modalities

Distinct payloads and conjugation of mAbs, peptides, ligonucleotides, high-potency and cytotoxic compounds.

Scientific Acumen

Deep expertise in payload and linker chemistry, built across many client programs and payload classes.

Flexible Options

Tailored commercial models with dedicated project management for every program.

Let's talk about your ADC program

Tell us where your program stands: Discovery, IND-enabling or clinical, and our ADC team will follow up.

• One scientific point of contact across mAb, payload, linker and conjugation
• Dedicated project management from screening through GMP
• NDA available before any detailed discussion